Cancer of the gastroesophageal junction: Combined modality therapy Journal Article


Author: Ilson, D. H.
Article Title: Cancer of the gastroesophageal junction: Combined modality therapy
Keywords: cancer surgery; clinical trial; review; cancer localization; postoperative period; bevacizumab; cisplatin; erlotinib; fluorouracil; cancer combination chemotherapy; multimodality cancer therapy; united states; paclitaxel; cancer radiotherapy; preoperative care; combined modality therapy; neoadjuvant therapy; lymph node metastasis; antineoplastic agent; cancer incidence; adenocarcinoma; bone marrow suppression; esophagitis; mucosa inflammation; nausea; cetuximab; cancer mortality; vinblastine; irinotecan; monoclonal antibody; panitumumab; protein tyrosine kinase inhibitor; celecoxib; cyclooxygenase 2 inhibitor; gefitinib; epirubicin; cancer epidemiology; platinum complex; trastuzumab; mitomycin; esophageal adenocarcinoma; stomach neoplasms; esophageal neoplasms; esophagectomy; lower esophagus sphincter; epidermal growth factor receptor kinase inhibitor; esophagogastric junction; matuzumab
Journal Title: Surgical Oncology Clinics of North America
Volume: 15
Issue: 4
ISSN: 1055-3207
Publisher: Elsevier Inc.  
Date Published: 2006-10-01
Start Page: 803
End Page: 824
Language: English
DOI: 10.1016/j.soc.2006.07.011
PUBMED: 17030275
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 6" - "Export Date: 4 June 2012" - "CODEN: SOCAF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David H Ilson
    433 Ilson